Rationale and design of a multicenter, double-blinded, randomized, placebo-controlled trial to investigate the effects of naldemedine on opioid-induced constipation for patients with cancer pain: A study protocol.

Author: AriyoshiKeisuke, DokiKosuke, HamanoJun, HigashibataTakahiro, HirakawaMami, HommaMasato, HorieYoshiki, HoriuchiManabu, KajiuraShinya, KessokuTakaomi, KiharaKota, KonishiKumi, MoritaTatsuya, MoriwakiToshikazu, NagaokaHiroka, NakajimaAtsushi, OyamadaShunsuke, ShimizuMasaki, TakashimaYasuyuki, YamadaTakeshi, YamamotoYoshiyuki, YamanakaYohei

Paper Details 
Original Abstract of the Article :
BACKGROUND: It is unclear which laxatives are appropriate to prevent opioid-induced constipation (OIC). This study will evaluate whether prophylactic use of naldemedine prevents OIC in patients with cancer who start opioid administration. METHODS: This study is a multicenter, double-blinded, random...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372594/

データ提供:米国国立医学図書館(NLM)

Naldemedine for Opioid-Induced Constipation: A New Oasis in the Desert of Pain Management

Opioid-induced constipation (OIC), a common side effect of opioid therapy, can be like a stubborn sandstorm in the digestive system. This study, like a team of researchers seeking a solution in the desert of pain management, investigates the potential of naldemedine, a peripherally acting mu-opioid receptor antagonist, to prevent OIC in patients with cancer pain. The authors outline the design of a multicenter, double-blinded, randomized, placebo-controlled trial to assess the effectiveness of prophylactic naldemedine in preventing OIC. This research aims to provide much-needed clarity on the best approach to managing OIC, potentially offering a new oasis in the desert of pain management.

Naldemedine: A Potential New Standard for OIC Prophylaxis

This study holds significant promise for patients experiencing OIC. If naldemedine proves effective in preventing OIC, it could become a new standard of care for this common and often debilitating side effect of opioid therapy. It's a potential game changer in the field of pain management.

Naldemedine: A Guiding Light in the Desert of Opioid Therapy

Opioid therapy can be a vital tool for managing pain, but it's important to address the challenges associated with OIC. This research offers a glimmer of hope for patients seeking a more effective and less invasive approach to managing this side effect. It's a reminder that even in the complex landscape of pain management, there are often solutions to be found.

Dr.Camel's Conclusion

Naldemedine is like a refreshing oasis in the desert of opioid-induced constipation. This study holds promise for developing a new and effective strategy for preventing this common side effect of opioid therapy. It's a reminder that even in the most challenging medical landscapes, there are often new discoveries waiting to be made.

Date :
  1. Date Completed n.d.
  2. Date Revised 2022-08-16
Further Info :

Pubmed ID

35967517

DOI: Digital Object Identifier

PMC9372594

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.